Advertisement

Topics

Companies Related to "Phase studies with filgotinib small bowel fistulizing Crohn" [Most Relevant Company Matches] - Page: 5 RSS

09:41 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "Phase studies with filgotinib small bowel fistulizing Crohn" found in our extensive corporate database of over 50,000 company records.

Showing "Phase studies with filgotinib small bowel fistulizing Crohn" Companies 101–125 of 3,400+

Relevant

TransPharma Medical Ltd.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing its proprietary active transdermal drug delivery technology. The company aims to develop multiple drug products through strategic partnerships with leading pharmaceutical companies and through indep...


DP Clinical

DP Clinical is a privately-held, minority-owned contract research organization (CRO) located in the I-270 Technology Corridor in Rockville, Maryland serving pharmaceutical and biotechnology clients. Providing our clients with monitoring, data management, analysis, and biostatistics for Phase I – IV clinical trials, DP Clinical has built a strong reputation for high standards of quality, data int...

ConSynance Therapeutics, Inc.

ConSynance Therapeutics is a clinical-stage drug development company based in Rensselaer, New York. The company’s pipeline includes innovative treatments for nonalcoholic steatohepatitis (NASH), the orphan disease Prader-Willi syndrome, and irritable bowel syndrome. ConSynance are collaborating with Chengdu SciMount Pharmatech Co., Ltd., a drug discov...


Covance Bio

Covance Bio process development, phase I/II, and small scale cGMP manufacturing facility.

Depomed, Inc. & Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood’s GC-C agonist, is in Phase 3 clinical development for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. The efficacy portion of linaclotide’s ...

Worldwide Clinical Trials

Accelerate Your Development Program with Pinpoint Therapeutic Focus and Complete Spectrum of Services Worldwide Clinical Trials is a global CRO that provides full-service drug development services to the pharmaceutical and biotechnology industries.   As one of the most innovative and scientifically-driven contract research organizations, we offer exceptionally strong clinical trial m...

Lycera Corp.

Lycera Corp. is focused on the discovery and development of small-molecule immunomodulators for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, lupus erythematosis, inflammatory bowel disease and transplant rejection. Originally founded by Dr. Gary Glick as a spin-out of the University of Michigan, Lycera is developing drug candidates that target two novel therape...

Telik

Telik, Inc. (Nasdaq: TELK) of Palo Alto, CA is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. Our most advanced development candidate is TELCYTA™ (TLK286), a novel cancer cell-activated chemotherapeutic currently in four Phase 3 registration trials in advanced ovarian cancer and non-small...

Esperion Therapeutics Inc.

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally avail...

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals is a privately held biotechnology company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis...

Trial Management Group Inc

Trial Management Group Inc. is a Site Management Organization (SMO) that was formed in 1995 by John C. Akitt and Scott Guidolin in order to promote the participation of a primary care physicians in medical research studies. Coming from pharmaceutical sales backgrounds and knowing that the majority of clinical trials were still being conducted at universities and/or teaching hospitals, John and Sco...

Perry Scientific, Inc.

Perry Scientific offers customized preclinical research services to support the development of new drugs and devices through the various stages of development.Perry Scientific can perform your studies or your scientists can use our vivarium and procedure rooms to perform their own studies. Our NIH and USDA registered facilities house most species of both large and small animals. We offer a broad r...

Spectrum Pharmaceuticals Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets six hematology/oncology drugs and has an advanced stage pipeline that has the potential to transform the company. Spectrum's strong track record for in-l...

Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (NASDAQ-PPHM) is a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection. The Company is advancing three separate clinical programs with its lead product candidates bavituximab and Cotara®. Bavituximab and Cotara are both in Phase II clinical studies for the treatment o...

Exelixis, Inc.

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with signi...

Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. A Phase 1B clinical trial evaluating its oral small molecule checkpoint inhib...

Probably Relevant

Pharmaceutical Profiles

Pharmaceutical Profiles is an early phase development company dedicated to improving the decision making process in early drug/product development.Pharmaceutical Profiles assists the global pharmaceutical industry to make the right product development decisions in early clinical development. We undertake studies for pharmaceutical and drug delivery companies based in North America, Europe and Japa...

Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a world leader in discovery and development of novel small interfering RNA, or siRNA, therapeutics for unmet medical needs. RNA interference is a biological process in which RNA molecules regulate expression of targeted genes. Quark’s fully integrated drug discovery and development platform spans the process from therape...

California Clinical Trials (CCT)

Since 1981 California Clinical Trials (CCT) has been at the forefront of drug development. Our best-in-class clinical experts, research staff, and trained physicians all work together seamlessly to bring hope to patients around the world. Our executive team comprises outstanding leaders in medical science. Whether you need careful patient selection for your Phase 1 studies, or experience in drug d...

Harbor BioSciences, Inc.

Harbor BioSciences is a development-stage company with two product candidates in clinical trials: Apoptone (HE3235), in the cohort expansion portion of a Phase I/IIa trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone and Triolex represent the lead candidates from Harbor BioSciences' small molecule platform bas...

TEMCO INC

The Continuous Wave Technique (CWT) methodology was introduced in 1996 by IKU Petroleum Research (now SINTEF Petroleum Research) as a method for measuring the acoustic velocities on small core samples, including in particular shale drill cuttings. The CWT technology is a fast and inexpensive method of measuring the ultrasonic wave velocity on samples as small as sub-millimeter in thickness. This i...

Abt Associates

Abt Bio-Pharma Solutions, Inc. (ABS) provides integrated clinical, health economic, and commercialization services to the pharmaceutical, biotechnology, medical device, and diagnostics industries worldwide. The company specializes in demonstrating the value, safety, and efficacy of health technologies through prospective studies as well as through retrospective data analyses, models, and quantitat...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

Pharma Biresearch

Pharma Bio-Research is an independent CRO, located in The Netherlands. We offer the full range of services for phase I/IIA clinical research, bioanalysis and biometrics with the most competitive time lines, excellent quality, reliability and efficiency. Reducing timelines to a minimumComplete integration of activities (clinical research, bioanalysis and biometrics/statistics) enables efficient man...

Aeolus Pharmaceuticals, Inc.

Aeolus is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation. AEOL 10150 is a patented, small molecule catalytic antioxidant that mimics and thereby amplifies the body’s natural enzymatic systems for eliminating reactive oxygen sp...


More From BioPortfolio on "Phase studies with filgotinib small bowel fistulizing Crohn"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks